{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T22:25:20Z","timestamp":1785363920815,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Rob and Karen Hale Distinguished Chair in Surgical Oncology"},{"name":"Pamela and Nick Gelsomini Breast Surgical Oncology Fellowship Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1245\/s10434-020-09073-6","type":"journal-article","created":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T16:04:33Z","timestamp":1598889873000},"page":"1358-1367","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Axillary Management After Neoadjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer"],"prefix":"10.1245","volume":"28","author":[{"given":"Olga","family":"Kantor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melia","family":"Wakeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Laws","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Grossmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Mittendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tari A.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,31]]},"reference":[{"issue":"8","key":"9073_CR1","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1093\/annonc\/mdx308","volume":"28","author":"G Curigliano","year":"2017","unstructured":"Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017;28(8):1700\u201312.","journal-title":"Ann Oncol."},{"issue":"11","key":"9073_CR2","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1001\/jamaoncol.2016.1897","volume":"2","author":"LM Spring","year":"2016","unstructured":"Spring LM, Gupta A, Reynolds KL, et al. Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(11):1477\u201386.","journal-title":"JAMA Oncol."},{"issue":"17","key":"9073_CR3","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1200\/JCO.2010.31.6950","volume":"29","author":"MJ Ellis","year":"2011","unstructured":"Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype\u2014ACOSOG Z1031. J Clin Oncol. 2011;29(17):2342\u20139.","journal-title":"J Clin Oncol."},{"issue":"4","key":"9073_CR4","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1097\/SLA.0000000000000924","volume":"260","author":"JC Boughey","year":"2014","unstructured":"Boughey JC, McCall LM, Ballman KV, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg. 2014;260(4):608\u201316.","journal-title":"Ann Surg."},{"issue":"13","key":"9073_CR5","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1245\/s10434-019-07785-y","volume":"26","author":"A Weiss","year":"2019","unstructured":"Weiss A, Wong S, Golshan M, et al. Patterns of axillary management in stages 2 and 3 hormone receptor-positive breast cancer by initial treatment approach. Ann Surg Oncol. 2019;26(13):4326\u201336.","journal-title":"Ann Surg Oncol."},{"key":"9073_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41523-020-00177-6","volume":"6","author":"O Kantor","year":"2020","unstructured":"Kantor O, Wong S, Weiss A, et al. Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer. NPJ Breast Cancer. 2020;6:35.","journal-title":"NPJ Breast Cancer."},{"issue":"3","key":"9073_CR7","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1245\/s10434-007-9747-3","volume":"15","author":"KY Bilimoria","year":"2008","unstructured":"Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15(3):683\u201390.","journal-title":"Ann Surg Oncol."},{"issue":"10","key":"9073_CR8","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017;318(10):918\u201326.","journal-title":"JAMA."},{"issue":"12","key":"9073_CR9","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","volume":"15","author":"M Donker","year":"2014","unstructured":"Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303\u201310.","journal-title":"Lancet Oncol."},{"issue":"8","key":"9073_CR10","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMoa020128","volume":"347","author":"B Fisher","year":"2002","unstructured":"Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347(8):567\u201375.","journal-title":"N Engl J Med."},{"issue":"10","key":"9073_CR11","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S1470-2045(07)70278-4","volume":"8","author":"DN Krag","year":"2007","unstructured":"Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8(10):881\u20138.","journal-title":"Lancet Oncol."},{"issue":"10","key":"9073_CR12","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S1470-2045(10)70207-2","volume":"11","author":"DN Krag","year":"2010","unstructured":"Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927\u201333.","journal-title":"Lancet Oncol."},{"issue":"5","key":"9073_CR13","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1008108","volume":"364","author":"DL Weaver","year":"2011","unstructured":"Weaver DL, Ashikaga T, Krag DN, et al. Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med. 2011;364(5):412\u201321.","journal-title":"N Engl J Med."},{"issue":"1","key":"9073_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s10549-017-4157-0","volume":"163","author":"TJ van Nijnatten","year":"2017","unstructured":"van Nijnatten TJ, Simons JM, Moossdorff M, et al. Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases. Breast Cancer Res Treat. 2017;163(1):159\u201366.","journal-title":"Breast Cancer Res Treat."},{"issue":"11","key":"9073_CR15","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.1245\/s10434-019-07517-2","volume":"26","author":"SM Wong","year":"2019","unstructured":"Wong SM, Almana N, Choi J, et al. Prognostic significance of residual axillary nodal micrometastases and isolated tumor cells after neoadjuvant chemotherapy for breast cancer. Ann Surg Oncol. 2019;26(11):3502\u20139.","journal-title":"Ann Surg Oncol."},{"issue":"9","key":"9073_CR16","doi-asserted-by":"publisher","first-page":"e0162605","DOI":"10.1371\/journal.pone.0162605","volume":"11","author":"C Geng","year":"2016","unstructured":"Geng C, Chen X, Pan X, Li J. The feasibility and accuracy of sentinel lymph node biopsy in initially clinically node-negative breast cancer after neoadjuvant chemotherapy: a systematic review and meta-analysis. PLoS One. 2016;11(9):e0162605.","journal-title":"PLoS One."},{"issue":"4","key":"9073_CR17","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/SLA.0b013e3181b8fd5e","volume":"250","author":"KK Hunt","year":"2009","unstructured":"Hunt KK, Yi M, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009;250(4):558\u201366.","journal-title":"Ann Surg."},{"issue":"14","key":"9073_CR18","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455\u201361.","journal-title":"JAMA."},{"issue":"7","key":"9073_CR19","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","volume":"14","author":"T Kuehn","year":"2013","unstructured":"Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609\u201318.","journal-title":"Lancet Oncol."},{"issue":"3","key":"9073_CR20","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","volume":"33","author":"JF Boileau","year":"2015","unstructured":"Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33(3):258\u201364.","journal-title":"J Clin Oncol."},{"issue":"11","key":"9073_CR21","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/j.ejso.2017.07.023","volume":"43","author":"G Martelli","year":"2017","unstructured":"Martelli G, Miceli R, Folli S, et al. Sentinel node biopsy after primary chemotherapy in cT2 N0\/1 breast cancer patients: long-term results of a retrospective study. Eur J Surg Oncol. 2017;43(11):2012\u201320.","journal-title":"Eur J Surg Oncol."},{"issue":"3","key":"9073_CR22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ejso.2015.11.019","volume":"42","author":"V Galimberti","year":"2016","unstructured":"Galimberti V, Ribeiro Fontana SK, Maisonneuve P, et al. Sentinel node biopsy after neoadjuvant treatment in breast cancer: five-year follow-up of patients with clinically node-negative or node-positive disease before treatment. Eur J Surg Oncol. 2016;42(3):361\u20138.","journal-title":"Eur J Surg Oncol."},{"issue":"10","key":"9073_CR23","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.1245\/s10434-019-07540-3","volume":"26","author":"MK Srour","year":"2019","unstructured":"Srour MK, Tseng J, Luu M, Alban RF, Giuliano AE, Chung A. Patterns in the use of axillary operations for patients with node-positive breast cancer after neoadjuvant chemotherapy: a national cancer database (NCDB) analysis. Ann Surg Oncol. 2019;26(10):3305\u201311.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"9073_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/jso.20010","volume":"85","author":"T Aihara","year":"2004","unstructured":"Aihara T, Munakata S, Morino H, Takatsuka Y. Feasibility of sentinel node biopsy for breast cancer after neoadjuvant endocrine therapy: a pilot study. J Surg Oncol. 2004;85(2):77\u201381.","journal-title":"J Surg Oncol."},{"issue":"4","key":"9073_CR25","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ejso.2016.12.011","volume":"43","author":"\u00c1 S\u00e1volt","year":"2017","unstructured":"S\u00e1volt \u00c1, P\u00e9ley G, Polg\u00e1r C, et al. Eight-year follow up result of the OTOASOR trial: the optimal treatment of the axilla\u2013surgery or radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: a randomized, single centre, phase III, non-inferiority trial. Eur J Surg Oncol. 2017;43(4):672\u20139.","journal-title":"Eur J Surg Oncol."},{"issue":"1","key":"9073_CR26","first-page":"29","volume":"39","author":"JL Phillips","year":"2012","unstructured":"Phillips JL, Stewart A. Scoping it out: a change in sentinel lymph node surgery coding practice. J Regist Manag. 2012;39(1):29\u201334.","journal-title":"J Regist Manag."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-09073-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-020-09073-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-09073-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T23:04:53Z","timestamp":1630364693000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-020-09073-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,31]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["9073"],"URL":"https:\/\/doi.org\/10.1245\/s10434-020-09073-6","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,31]]},"assertion":[{"value":"21 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Elizabeth A. Mittendorf reports the following personal financial interests: research support for laboratory from GlaxoSmithKline; honoraria from Physician Education Resource; compensated service on Scientific Advisory Boards for Astra-Zeneca, Exact Sciences (formerly Genomic Health), Merck, Peregrine Pharmaceuticals, Roche\/Genentech, Sellas Lifesciences, TapImmune Inc; and uncompensated service on steering committees for BMS, Lilly, Roche\/Genentech. She also reports the following institutional financial interests: MD Anderson: clinical trial funding from AstraZeneca, EMD Serono, Galena Biopharma, Roche\/Genentech; DFCI: clinical trial funding from Roche\/Genentech (via an SU2C Grant); and the following non-financial interests and non-remunerated activities: Board of Directors: American Society of Clinical Oncology, Scientific Advisor: Susan G. Komen for the Cure Foundation. Tari A. King reports speaker\u2019s fees and advisory board participation for Exact Sciences (formally Genomic Health).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}